Biotechnology

Canyon Labs Expands Capabilities With Acquisition of Life Pack Labs

October 8, 2024 9:00 AM

Utah-based Canyon Labs announces its strategic acquisition of Life Pack Labs in California, broadening its service offerings and enhancing its position as an industry leader in medical device and pharmaceutical compliance testing. SALT LAKE CITY, UT / ACCESSWIRE / October 8, 2024 / Canyon Labs, a leading medical device & pharmaceutical consulting, sterility assurance, analytical chemistry and package testing provider, is proud to announce the...

Read more

Kelly Keegan Joins Qr8 Health as Chief Commercial Officer

October 8, 2024 9:00 AM

Keegan to Lead Strategic Growth and Drive AI-Enabled Innovation in Digital Cognitive Health Solutions CLEVELAND, OH / ACCESSWIRE / October 8, 2024 / Qr8 Health announced the appointment of Kelly Keegan as Chief Commercial Officer (CCO). Keegan brings more than 30 years of experience as a dynamic and entrepreneurial leader in the healthcare industry. His career is marked by significant contributions to building and expanding organizations in...

Read more

Ensysce Biosciences Announces Leadership Team’s Participation in the Annual Pain Therapeutics Summit

October 8, 2024 8:00 AM

Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced that Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce, will present at the 18th Annual Pain Therapeutics Summit taking place on October 28 and 29, 2024 in Boston, MA. Dr. Kirkpatrick's presentation "When...

Read more

Next Gen Diagnostics Announces Agreement to Develop Sequence-Based Susceptibility Determination of Cefiderocol

October 7, 2024 8:00 AM

CAMBRIDGE, MA / ACCESSWIRE / October 7, 2024 / Next Gen Diagnostics (NGD), a world leader in the development of validated machine learning models for whole genome sequence-based determination of bacterial susceptibility to antibiotics, announces an agreement with Shionogi & Co., Ltd. (Shionogi) to develop models to predict susceptibility to cefiderocol. Shionogi is a global research-driven pharmaceutical company based in Japan and is the...

Read more

FluoGuide A/S submits Clinical Trial Application for phase II trial in head and neck cancer

October 7, 2024 7:30 AM

KØBENHAVN, DK / ACCESSWIRE / October 07, 2024 / FluoGuide A/S (STO:FLUO) Copenhagen, Denmark - FluoGuide A/S ("FluoGuide" or the "Company"), a biothech company specializing in precision cancer surgery, today announced the submission of the Clinical Trial Application (CTA) for phase II trial in head and neck cancer (oral squamous cell carcinoma cancer). Redeye will host a live streaming event regarding the head and neck trial on 18 October 2024,...

Read more

IGC Pharma Wins 2 Prizes in Phase 1 of National Institutes of Health's AI PREPARE Challenge

October 3, 2024 9:00 AM

IGC Pharma, Inc. (NYSE American:IGC) proudly announces that it won 2 awards in the PREPARE Challenge (Pioneering Research for Early Prediction of Alzheimer's and Related Dementias EUREKA Challenge), with its entry of the Mexican Health and Aging Study ("MHAS") database. IGC Pharma, Inc. The PREPARE Challenge is sponsored by the National Institute on Aging ("NIA"), an institute of the National Institutes of Health ("NIH"). The competition...

Read more

CB Scientific, Inc. Appoints Trip Thomas as Chief Financial Officer

October 3, 2024 9:00 AM

LAS VEGAS, NV / ACCESSWIRE / October 3, 2024 / CB Scientific, Inc. (OTC PINK:CBSC) ("CBSC" or the "Company"), a designer, manufacturer and distributor of non-invasive ambulatory cardiac monitoring products and services, announced today that the Company's Board of Directors appointed Mr. William "Trip" Thomas as its Chief Financial Officer effective October 1, 2024. Mr. Thomas is replacing Ms. Brooke Turk who formally tendered her resignation...

Read more

Biovica Announces Outcome of Exercise of Warrants of Series To 3 B

October 3, 2024 2:20 AM

UPPSALA, SWEDEN / ACCESSWIRE / October 3, 2024 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) Biovica International AB ("Biovica" or the "Company") announces today the outcome of the exercise of warrants of series TO 3 B issued in connection with the Company's rights issue of units during October 2023. In total, 7,441,387 warrants were exercised for subscription of the equivalent amount of class B shares in the Company,...

Read more

SOHM, Inc. Continues to Build its IP Portfolio in the Gene Editing and Cell Engineering Space

October 2, 2024 10:00 AM

SOHM, Inc. (OTC PINK:SHMN), a pharmaceutical and biotechnology company specializing in generic drugs, has announced today that the company has filed new provisional patent application with USPTO. Dr. David Aguilar, COO, SOHM, Inc. announced that the company has filed a new provisional application entitled; "DONOR NUCLEIC ACIDS FOR RNA GUIDED INTEGRASES AND MULTIPLEX GUIDE RNA SYSTEM FOR TARGETING" Dr. Aguilar further added that the application...

Read more

Adolore BioTherapeutics to Present at 18th Annual Pain Therapeutics Summit

October 2, 2024 10:00 AM

DELRAY BEACH, FL / ACCESSWIRE / October 2, 2024 / Adolore BioTherapeutics ("Adolore" or the "Company"), a biotechnology company developing transformational opioid-free intracellularly-delivered treatments for chronic pain, today announced that Roy C. Levitt, MD, the Company's founder, Chief Medical Officer, and Executive Chairman, Clinical Professor, University of Miami, and Principal Investigator of a NIH, NINDS, HEAL UH3 Award will present at...

Read more

Ensysce Biosciences Provides Shareholder Update, Responds to Recent Shareholder Inquiries

October 2, 2024 8:00 AM

Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today provides a response from Chief Executive Officer, Dr. Lynn Kirkpatrick, regarding recent inquiries from stockholders and other interested parties. Dear Fellow Stockholders, It is important to me to directly deliver an...

Read more

Moolec Science Presents Fiscal Year 2024 Annual Business Update

October 2, 2024 6:00 AM

LUXEMBOURG / ACCESSWIRE / October 2, 2024 / Moolec Science SA (NASDAQ:MLEC) ("The Company"; "Moolec"), a science-based food ingredient company focused on producing animal proteins and nutritional oils in plants, today reported its Business Update for the fourth quarter of Fiscal Year 2024 ended June 30, 2024. Moolec Science Logo The main highlights of Moolec's fourth quarter are as follows: GLASO™: The Company announced an offtake agreement...

Read more

Adnexus Biotechnologies Unveils Sutra(TM), a Game-Changing AI Platform for Drug Discovery and Infectious Disease Research

October 1, 2024 8:00 AM

DALLAS, TX / ACCESSWIRE / October 1, 2024 / Adnexus Biotechnologies Inc., a pioneering company in Artificial Intelligence-driven innovations for early drug discovery and infectious disease research, is pleased to announce its new AI Empowered Drug Discovery Platform, Sutra™. The Sutra™ AI platform has not just confirmed decades of work, but also added new targets for monoclonal antibodies within weeks, receiving independent validation of their...

Read more

Vicore Announces Investment from Sanofi

September 30, 2024 1:15 PM

Vicore Pharma Holding AB (STO:VICO), a clinical-stage biopharmaceutical company unlocking the potential of a novel class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), today announces an investment from Sanofi in Vicore through a commitment to subscribe for shares in the ongoing rights issue corresponding to a total of approximately USD 10.0 million (approximately SEK 102.0 million). The commitment entails a subscription...

Read more

Tharimmune Signs Nonbinding Letter of Intent to Merge With Intract Pharma to Create Transformative Oral Biologic Therapeutics Company

September 30, 2024 7:00 AM

- Business combination to form a best-in-class, transformative oral biologics company - Synergies between Tharimmune's clinical-stage assets and Intract's delivery platform to drive pipeline growth - Merger anticipated to close in 1Q25 BRIDGEWATER, NJ and LONDON, UK / ACCESSWIRE / September 30, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in...

Read more

Ondine Biomedical Reports Robust Growth in H1 2024

September 30, 2024 5:05 AM

Ondine Biomedical Inc. (AIM:OBI), a leading provider of light-activated antimicrobial technology to prevent and treat hospital infections, is pleased to announce strong operational results for the first half of 2024, highlighting significant progress and expansion in its commercial and clinical endeavors. Financial figures throughout this interim report are in Canadian dollars unless otherwise specified. Operational Highlights · Commercial...

Read more

Ondine Biomedical Reports Robust Growth in H1 2024

September 30, 2024 2:00 AM

Ondine Biomedical Inc. ("Ondine Biomedical", "Ondine" or the "Company") (AIM:OBI), a leading provider of light-activated antimicrobial technology to prevent and treat hospital infections, is pleased to announce strong operational results for the first half of 2024, highlighting significant progress and expansion in its commercial and clinical endeavors. Financial figures throughout this interim report are in Canadian dollars unless otherwise...

Read more

Ensysce Biosciences Receives Notice from Nasdaq

September 27, 2024 4:30 PM

Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, has received notice from the listing qualifications department staff of The Nasdaq Stock Market ("Nasdaq") stating that the Company has not regained compliance with Nasdaq Listing Rule 5550(a)(2) because the bid price for the...

Read more

enVVeno Medical Corporation Announces Pricing of $15.0 Million Public Offering

September 26, 2024 10:20 PM

enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced the pricing of an underwritten public offering led by existing institutional investors of 4,285,715 shares of its common stock (or pre-funded warrants in lieu thereof) at a public offering price of $3.50 per share. The pre-funded warrants will be immediately exercisable and may be...

Read more

enVVeno Medical Corporation Announces Proposed Public Offering

September 26, 2024 4:05 PM

enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced that it is proposing to offer and sell, subject to market conditions, shares of its common stock (or pre-funded warrants in lieu thereof) in an underwritten public offering. enVVeno expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the number of...

Read more